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The double-stranded RNA-dependent protein kinase (PKR) is believed to mediate cellular antiviral responses, function
as a tumor suppressor, and regulate cell growth and differentiation. Its activation is dependent on double-stranded
RNA (dsRNA) structures but these interactions are not fully understood. The possibility of direct interaction between
dsRNA and the arginine and lysine-rich region of PKR (residues 54 – 74) was examined using synthetic peptides. We
found that addition of a synthetic peptide corresponding to residues 54 – 74 of murine PKR or residues 60 – 80 of human
PKR inhibited the autophosphorylation and activation of the kinase by either poly(I) – poly(C) or the 82-nucleotide-long
TAR RNA. Gel-shift analysis indicated that the peptides disrupted the kinase – TAR complex by binding directly to TAR
RNA. These findings delineate at least one dsRNA-binding domain in PKR which may be important for its cellular
activation. q 1996 Academic Press, Inc.
INTRODUCTION and modulates the activity of PKR (Clarke et al., 1991;
Kitajewski et al., 1986; Hovanessian, 1989; Hunter et al.,
The double-stranded RNA-dependent eIF-2a kinase
1975; SenGupta and Silverman, 1989; Roy et al., 1991;
(PKR) is a serine/threonine protein kinase (Petryshyn et
Edery et al., 1989; Judware et al., 1993; Bischoff and
al., 1994; Jaramillo et al., 1995). It is induced by interferon
Samuel, 1989), there does not appear to be sequenceand mediates its antiviral activity and has been impli-
specificity. However, there is a dependency on both thecated in the regulation of a number of cellular processes
length of the double-strandedness and its secondary(Sen and Lengyel, 1992; Kalvakolanu and Borden, 1996).
structure (Manche et al., 1992; Ghadge et al., 1994;The cellular effects of PKR have generally been attrib-
Hunter et al., 1975; Edery et al., 1989). Tertiary structureuted to translational regulation by a mechanism which
is also likely to be important. Several viral RNAs inhibitis largely understood (Farrell et al., 1977; Petryshyn et
the activation of PKR (Kitajewski et al., 1986; Clarke etal., 1983; Samuel, 1979, 1993). In the presence of low
al., 1991; Ghadge et al., 1994), while others are efficientconcentrations of dsRNA, divalent cations, and ATP, PKR
activators (Hovanessian, 1989).undergoes phosphorylation which is required to convert
The TAR sequence of HIV-1 mRNA transcript has beenthe enzyme from a latent to an active protein kinase
shown to both activate (Edery et al., 1989; SenGupta(Lebleu et al., 1976; Petryshyn et al., 1983). Paradoxically,
and Silverman, 1989; Judware et al., 1993) and preventthe phosphorylation and activation is prevented by high
activation (Gunnery et al., 1990) of PKR at low concentra-concentrations of dsRNA (Farrell et al., 1977; Hunter et
tions. The reason for the different observations is un-al., 1975). Once activated, however, PKR phosphorylates
clear. However, recently, it has been shown that a chemi-the a subunit of the eukaryotic initiation factor 2 (eIF-2a)
cally synthesized TAR RNA (57 nucleotides in length) was(Farrell et al., 1977; Lebleu et al., 1976; Petryshyn et al.,
intrinsically able to activate PKR (Maitra et al., 1994). This1983), which in turn, results in inhibition of protein synthe-
suggests that differences in the preparation of PKR rathersis (London et al., 1987; Hershey, 1989).
than TAR RNA may contribute to the observed differencesThe mechanism by which PKR interacts with dsRNA
in its activation.is unclear. The spatial, structural, and sequence require-
Both human (Meurs et al., 1990) and murine PKR (Fengments within the RNA or the protein itself are not suffi-
et al., 1992; Baier et al., 1993) have been cloned andciently resolved to fully understand the dynamics of this
sequenced and these two cDNAs share extensive nucle-interaction. Since a diverse group of viral RNAs interacts
otide sequence identity (Feng et al., 1992). Moreover,
results from several studies have indicated that the regu-
1 To whom correspondence and reprint requests should be ad- latory and RNA-binding domains of PKR are localized todressed at Center for Cancer and Transplantation Biology, Children’s
the N-terminal portion of the kinase (Feng et al., 1992;National Medical Center, 111 Michigan Ave., NW, Washington, DC
20010. Fax: (202) 884-3929. McCormack et al., 1992; Patel et al., 1994; Green and
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Mathews, 1992; Patel and Sen, 1992). These studies have label TAR RNA, the same reaction was performed except
that 10–20 mCi of [a-32P]CTP (3000 Ci/mmol) was added.also delineated several amino acid regions having poten-
tial for dsRNA binding, such as residues 55–75 (hRI) in
human PKR. Disruption of this sequence by deletion or Protein kinase assays
amino acid substitution results in a mutant PKR which
Assays containing 4–5 ng of purified PKR from rabbithas lost its ability to bind dsRNA (Feng et al., 1992;
reticulocytes were performed with the indicated amountsMcMillan et al., 1995). These findings suggest that the
of dsRNA in a buffer containing 10 mM Tris–HCl (7.8), 2hRI sequence may be critical for expression of biological
mM Mg(OAc)2 , 50 mM KCl at 307. The reaction volumesactivity and may be a site at which the kinase is normally
were 20 ml. After 10 min of incubation the reactions wereregulated. In this study, the importance of the human
stopped by addition of 7 ml 41 SDS loading/denaturing(hRI) and mouse (RI) sequence for the activation of PKR
buffer. The samples were subjected to SDS–7.5% poly-was directly assessed using a synthetic peptide.
acrylamide gel electrophoresis and autoradiography
(Ernst et al., 1978). Kinase assays for HRI were essen-
MATERIALS AND METHODS tially the same except purified HRI was used.
Materials
RNA mobility-shift assays
[g-32P]ATP (3000 Ci/mmol) and [a-32P]CTP (3000 Ci/
Assays were performed as described elsewheremmol) were obtained from Amersham. eIF-2 and PKR
(Judware et al., 1993). Briefly, 50 ng of 32P-labeled TARfrom rabbit reticulocytes were purified as described (An-
RNA (approx 3 1 105 cpm/mg) was incubated in the pres-drews et al., 1985, and Petryshyn et al., 1983, respec-
ence of 5 ng of PKR under conditions for the kinasetively). Heme-regulated kinase (HRI) was purified as de-
assay. Complexes were resolved utilizing 10% nondena-scribed in Trachsel et al., 1978. Plasmid pSP64TAR-CAT
turing polyacrylamide gels. Mobility shift assays with thewas provided by Dr. Nahum Sonenberg (McGill Univer-
use of peptides were essentially the same except SDSsity) and is described in Parkin et al., 1988.
(2%) was added to some reactions before application to a
gel. To determine the relative amounts of phosphorylatedPeptide synthesis
PKR and eIF-2a, corresponding bands on autoradio-
Peptides were generated by automated Fmoc solid- grams were quantitated by scanning densitometry.
phase synthesis using Applied Biosystems Model 431
running in small-scale ‘‘Fastmoc’’ mode. Synthetic pep- RESULTS
tides were cleaved from the solid support using a TFA-
based method (King et al., 1990) followed by ether or Effect of peptides on the autophosphorylation of PKR
ethyl acetate precipitation, centrifugation, and vacuum
Synthetic peptides with identical sequences to the RIdesiccation. All reagents for synthesis and cleavage
and hRI regions were prepared and utilized to directlywere HPLC grade. Relative peptide purity was assessed
assess their role in PKR activation. The studies wereby reverse-phase C-18 HPLC and was typically ⁄80%.
carried out utilizing both a synthetic dsRNA [poly(I)–Composition was routinely verified by mass spectrome-
poly(C)] and the 83-nucleotide-long TAR RNA. A concen-try. RI peptide (AKGRSKQEARNAAAKLAVDIL) corre-
tration-dependent phosphorylation of PKR by TAR RNAsponds to residues 54–74 of murine PKR. hRI peptide
is shown in Fig. 1. The phosphorylation of PKR could be(residues KKEAKNAAAKLAVEILNKEKK) corresponds to
seen with as little as 200 ng/ml (Fig. 1, lane 1) and in-residues 60–80 of human PKR. Peptide 271 (DMLPKK-
creased as the concentration of TAR RNA was elevatedSEESAAPSR) and peptide 273 (SSAARPSGRRRDPAG)
to 2 mg/ml, the highest concentration tested (Fig. 1, laneswere selected for similarity of reverse-phase chromato-
2–4). No phosphorylation of PKR was observed in thegraphic properties and composition to the RI peptide.
absence of added RNA (Fig. 1, lane 5). In contrast, thePeptide 274 (KGSKNALAARVIAAAQRELKD) was synthe-
phosphorylation of PKR by poly(I)–poly(C) was observedsized as a random RI peptide.
with as little as 1 ng/ml and reached a maximum level
between 45 and 200 ng/ml poly(I)–poly(C) (data notTranscription of TAR RNA
shown). This is consistent with previous reports (Hunter
et al., 1975; Galabru and Hovanessian, 1987; Galabru etPlasmid pSP64 TAR-CAT containing a cDNA for TAR
RNA (nucleotides/1 to/82 of the HIV-1 LTR) was linear- al., 1989; Maitra et al., 1994). The higher level of TAR
RNA needed for phosphorylation of PKR is expected be-ized by HindIII and used as a template. Transcription
reactions were performed as recommended by Ambion, cause of its lower intrinsic dsRNA content relative to
poly(I)–poly(C) and is consistent with other studiesand contained Ambion transcription buffer, 7.5 mM GTP,
ATP, UTP, and CTP each, 1 mg of linearized plasmid, and (Edery et al., 1989; Roy et al., 1991; Judware et al., 1993;
Maitra et al., 1994). In subsequent experiments, we usedAmbion enzyme mix containing SP6 polymerase. To trace
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efficiently prevented the phosphorylation of PKR in the
presence of poly(I)–poly(C) (75% inhibition). Thus the RI
and hRI peptides were effective in blocking the phos-
phorylation of PKR by both TAR RNA and poly(I)–poly(C).
Effect of peptides on the phosphorylation of eIF-2
PKR once phosphorylated becomes converted to an
active enzyme which phosphorylates the a-subunit of
eIF-2. We therefore examined the effect of the RI peptide
on the phosphorylation of this physiologic substrate.
Concomitant with the inhibition in phosphorylation ofFIG. 1. Effect of TAR RNA on the phosphorylation of PKR. Protein
PKR, the RI peptide (80 mM) prevented the phosphoryla-kinase assays containing purified PKR were performed as described
under Materials and Methods. TAR RNA was added to all assays except tion of eIF-2a (Fig. 3, compare lanes 2 and 3, 75% inhibi-
for the experiment in lane 5, at the final concentrations indicated. Lane tion). The loss of eIF-2a phosphorylation appears largely
5 is a control assay containing no added TAR RNA. The extent of
due to a direct effect on PKR activation, because thePKR phosphorylation was determined following gel electrophoresis and
addition of RI peptide (80 mM) after the kinase had al-autoradiography as described under Materials and Methods. The mi-
gration positions and molecular weights (1103) of protein standards ready undergone subsequent phosphorylation and acti-
myosin (200 kDa), phosphorylase (92 kDa), bovine serum albumin (68 vation had no effect on the phosphorylation of eIF-2a
kDa), and ovalbumin (43 kDa) are indicated on the left. The arrow (Fig. 3, compare lanes 4 and 5). However, at high levels
indicates the position of PKR. The figure is an autoradiogram.
of RI peptide (400 mM), some inhibition of eIF-2a phos-
phorylation was observed in the presence of phosphory-
lated PKR (data not shown). The significance of this ob-45 ng/ml poly(I)–poly(C) and 2 mg/ml TAR RNA for
servation is unclear but may be due to additional effectsassays.
of the peptide on PKR. In addition to PKR and eIF-2aThe addition of either RI or hRI peptide to kinase reac-
several other phosphoprotein bands were observed (Fig.tions containing TAR RNA resulted in a concentration-
3, lanes 1–5), which represent contaminating phospho-dependent inhibition of PKR phosphorylation (Figs. 2A
proteins present in the eIF-2a preparation. These phos-and 2B). Quantitation of autoradiograms indicated that
phoproteins were observed in the absence of dsRNA andas little as 80 mM RI peptide resulted in 50% reduction
were largely unaffected by dsRNA or the RI peptide. Thisin PKR phosphorylation (Fig. 2A, lane 2) and complete
suggests that the RI peptide is not a nonspecific inhibitorinhibition was observed at 400 mM (Fig. 2A, lane 3). Simi-
of protein phosphorylation. This is further supported bylarly, addition of hRI peptide to kinase reaction containing
the observation that the RI peptide (400 mM) had little orTAR RNA resulted in 80% inhibition at 375 mM (Fig. 2B,
no effect on the autophosphorylation of either the HRI orlane 6), while 50% inhibition was observed at 150 mM
its substrate, which is also eIF-2a (Fig. 3, compare laneshRI peptide (Fig. 2B, lane 4). Moreover, the RI (80 mM,
Fig. 3, lane 3) and hRI peptides (375 mM, not shown) 6 and 7). Thus at low levels, the RI peptide prevents the
FIG. 2. Effect of RI and hRI peptide on the phosphorylation of PKR. The peptides were dissolved in H2O and added to protein kinase assays at
the final concentrations indicated. Protein kinase assays containing purified PKR and TAR RNA (2 mg/ml), gel electrophoresis, and autoradiography
were carried out as described for Fig. 1. (A) Effect of RI peptide. Lane 1, phosphorylation assay containing no peptide or TAR RNA. Lane 4, a control
assay containing no peptide. (B) Effect of hRI peptide. Lane 1, phosphorylation assay containing no peptide or TAR RNA. Lane 2, a control assay
containing no peptide. The figure is an autoradiogram.
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based on reactions containing 60 nM TAR RNA and 20
nM PKR and resulting in 23% binding of which 50% was
inhibited by peptide. This value is in reasonable
agreement with the amount of peptide (50–150 mM) ob-
served to inhibit the autophosphorylation of PKR by 50%
(Figs. 2 and 3). Thus an approximately 2500-fold molar
excess of peptide relative to PKR is required to efficiently
prevent binding of TAR RNA to PKR. This is not surprising
since short peptides are likely to be considerably less
efficient than native intact molecules. Preliminary studies
indicated that the peptide–TAR RNA complex may form
unusual aggregates which do not resolve well on gels. To
avoid this, the RNA mobility-shift assays were modified
to include the addition of SDS to the gel-shift reaction
FIG. 3. Effect of RI peptide on the phosphorylation of eIF-2a and
immediately before application to the gel. Under theseHRI. Protein kinase assays were carried out as described for Fig. 1.
conditions, RI and hRI peptide–TAR RNA complexesAll assays contained partially purified eIF-2 (0.5 mg). Poly(I)–poly(C) (45
ng/ml) and RI peptide (80 or 400 mM) were added to the assays where were formed and readily resolved (Fig. 5). It is of interest
indicated. Other additions were PKR (5 ng, lanes 1–5) and HRI (0.5 ng, to note that as the concentration of RI or hRI peptide was
lanes 6 and 7). In the assays shown in lanes 4 and 5, PKR was incu- elevated, the RNA mobility shift became more pro-
bated for 10 min at 307 with poly(I)–poly(C) to activate the kinase. The
nounced (Figs. 5A and 5B, compare lane 1 and lanes 2–reactions were chilled on ice and supplemented with eIF-2 and RI
4). This suggests that several molecules of each peptidepeptide (lane 5). These assays were incubated for an additional 10
min at 307 to determine the effect of RI peptide on eIF-2a phosphoryla- may bind to a single molecule of TAR RNA. Alternatively,
tion. The arrows indicate the migration position of HRI, PKR, and eIF- the binding of the peptides to TAR RNA may cause a
2a. The figure is an autoradiogram. change in the intrinsic structure of the RNA. Such struc-
tural change(s) have been recently demonstrated upon
binding of the ROM protein to ColE1 transcript RNA (Ma-autophosphorylation and activation of PKR but has little
rino et al., 1995). Binding of RI peptide to TAR RNAeffect once the kinase has been activated.
reached the plateau at concentrations between 160 and
240 mM, whereas binding of hRI peptide did not reach aEffect of peptides on the binding of TAR RNA to PKR
plateau at concentrations up to 400 mM. This suggests
a higher binding affinity for the RI peptide. Because ofSince the RI and hRI peptides potentially represent a
portion or all of the RNA binding domain of mouse and the apparent complexity of these interactions the binding
human PKR, respectively, it was important to examine
whether the peptides interfered with the binding of
dsRNA to PKR. In this regard it was also of interest to
determine whether the peptides could bind directly to
dsRNA. The interaction of PKR with TAR RNA has been
successfully studied using RNA mobility-shift analysis
(Edery et al., 1989; Roy et al., 1991; Judware et al., 1993;
Maitra et al., 1994). We utilized this method to examine
the effect of the peptides on the binding of PKR to TAR
RNA. RNA mobility-shift assays containing only highly
purified PKR (5 ng) and radiolabeled TAR gave rise to a
prominent slowly migrating RNA–protein complex when
separated on 10% polyacrylamide gel (Fig. 4, lane 2).
This complex appeared to be the result of a specific
interaction between PKR and TAR RNA because it was
FIG. 4. Effect of RI and hRI peptide on the binding of TAR RNA tonot observed in the absence of PKR (Fig. 4, lane 1) and
PKR. 32P-labeled TAR RNA (3 1 105 cpm/mg) was prepared by in vitro
it was markedly prevented (60%) by excess levels of unla- transcription as described under Materials and Methods. Assays con-
beled poly(I)–poly(C) (80 mg/ml) used as a specific com- taining radiolabeled TAR RNA were incubated under protein kinase
conditions in the presence or absence of purified PKR (5 ng) as indi-petitor to TAR RNA (Fig. 4, compare lanes 2 and 3). The
cated. Excess poly(I)–poly(C) (80 mg/ml) was added as a competitoraddition of either the hRI or the RI peptides (400 mM)
where indicated. Some assays received the RI or hRI peptide (400 mM).greatly reduced TAR RNA–PKR complex formation (Fig.
The reaction mixtures were separated by RNA mobility shift on 10%
4, lanes 4 and 5, respectively). An estimate of the inhibi- native polyacrylamide as described under Materials and Methods. The
tion constant for the peptides could be calculated from figure is an autoradiogram. Arrows on the left indicate position of the
free TAR RNA and the TAR RNA complexed to PKR.the data in Fig. 4. It was approximately 50 mM. This was
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FIG. 5. Binding of RI and hRI peptides to TAR RNA. RNA mobility-shift assays were performed as described for Fig. 4. All incubations contained
radiolabeled TAR RNA (3 1 105 cpm/mg, 50 ng) and the indicated final concentration of (A) RI peptide or (B) hRI peptide. One assay (lane 1)
contained no peptide. The reaction mixtures were resolved by electrophoresis on a 10% native polyacrylamide gel. Arrows on left indicate position
of free TAR RNA and TAR RNA complexed to the RI and hRI peptide. The figures are autoradiograms.
constants could not be determined under our experi- Nevertheless, these findings are consistent with RNA
mobility-shift analysis. None of the peptides 271, 273, ormental conditions. However, these formed complexes
could be eliminated by excess levels of poly(I) – poly(C) 274 formed a demonstrable complex with TAR RNA (Fig.
7, lanes 4–6) under conditions where a TAR RNA–RI or(80 mg/ml).
–hRI peptide complex was clearly evident (Fig. 7, lanes
Specificity of the peptide interaction with dsRNA 2 and 3).
To examine more closely the specificity of the pep- DISCUSSION
tides, several other synthetic peptides were utilized in
The goal of this study was to gain a better understand-protein kinase and RNA mobility-shift assays. Among
ing of the mechanism by which PKR is regulated, to delin-these were peptides 271 and 273, each of which have
eate the characteristic features of the peptide(s) requiredcomposition and reverse-phase chromatographic prop-
for RNA binding, and to identify novel peptides with po-erties similar to those of the RI and hRI peptides. Peptide
tential therapeutic value as kinase regulators. The data274 was an additional control, synthesized as a random
indicate that the 21-amino-acid-long synthetic peptidesRI peptide. The data in Fig. 6 indicate that under condi-
representing residues of 54–74 of murine PKR (RI pep-tions in which RI or hRI peptide (400 mM) markedly pre-
tide—AKGRSKQEARNAAAKLAVDIL) and residues 60–vent the poly(I)–poly(C)-dependent phosphorylation of
80 of human PKR (hRI peptide—KKEAKNAAAKLAVEI-PKR (Fig. 6, compare lanes 2 to lanes 3 and 4), peptides
LNKEKK) can effectively inhibit the activation of the ki-271, 273, or 274 (600 mM) had no significant effect (Fig.
nase by forming a direct complex with dsRNA. These6, lanes 5–7). We note that the addition of peptide 273
findings also suggest the RI or hRI peptides representto protein kinase assays was consistently associated
at least one important regulatory domain involved in acti-with the phosphorylation of several unidentified proteins.
vation of PKR. This conclusion is supported by the obser-The reason for this is unknown and not examined further.
vations that: (i) the peptides prevented the autophosphor-
ylation and activation of PKR by optimal concentrations
by either synthetic [poly(I)–poly(C)] or naturally occurring
TAR RNA dsRNA structures, (ii) the peptides also pre-
vented formation of the TAR RNA/PKR complex normally
observed by gel-shift mobility analysis (Roy et al., 1991;
Judware et al., 1993), and (iii) the peptides formed a sta-
ble complex with TAR RNA to function as inhibitors of
the kinase. These effects appear to be specific for the
RI and hRI peptides, since two distinct synthetic peptides
FIG. 6. Effect of peptides on the phosphorylation of PKR. Protein 15 residues in length but having similar hydrophobic/
kinase assays were carried out as described for Fig. 1. All assays hydrophilic and acid/base balance and a randomized
contained purified PKR (5 ng) and were incubated in the absence (lane control peptide had no effect on the autophosphorylation
1) and presence (lanes 2–7) of poly(I)–poly(C) (45 ng/ml). Other addi-
of PKR and did not form a complex with the RNA. Ourtions to the assay include RI peptide (400 mM, lane 3), hRI peptide (400
results also indicate that both peptides were not behav-mM, lane 4), peptide 271 (600 mM, lane 5), peptide 273 (600 mM, lane
6), and peptide 274 (400 mM, lane 7). The figure is an autoradiogram. ing simply as a general inhibitor of protein phosphoryla-
AID VY 7999 / 6a19$$$381 07-07-96 22:34:36 vira AP: Virology
198 NEKHAI ET AL.
as a closely related motif in vaccinia virus protein E3L
(McCormack et al., 1992; Green and Mathews, 1992).
Further analysis pointed to the placement of the basic
and acidic residues essentially on a single side of the
helical structure while hydrophobic residues occupy a
narrow region on the opposite side (McCormack et al.,
1992). Since the murine RI peptide is very close to the
human form, it is likely to have a similar secondary struc-
ture. Inspection of the murine RI peptide confirms a clus-
FIG. 7. Binding of peptides to TAR RNA. RNA mobility-shift assays
tering of alanine residues which are dispersed amongwere performed as described for Fig. 4. All assays contained radiola-
basic arginine and lysine residues (ARNAAAKLA), whichbeled TAR RNA (3 1 105 cpm/mg, 50 ng). Additions to reactions were
RI peptide (400 mM, lane 2), hRI peptide (400 mM, lane 3), peptide 271 conforms to a predicted a-helical RNA binding motif.
(600 mM, lane 4), peptide 273 (600 mM, lane 5), and peptide 274 (400 While the studies reported here delineate one dsRNA
mM, lane 6). Reactions were separated by electrophoresis on a 10% binding sequence within PKR, other sequences of inter-
native polyacrylamide gel. Lanes 1 and 7 are control reactions con-
est may exist. For example, region 143–166 of humantaining TAR RNA alone. The figure is an autoradiogram.
and murine PKR has some similarity in amino acid se-
quence to the RI and hRI peptide (Feng et al., 1992;
McCormack et al., 1992; Green and Mathews, 1992). De-tion, since they had no effect on either the autophosphor-
ylation or the activity of the heme regulating eIF-2a ki- letion analysis has suggested that this region is im-
portant for the growth-regulating property of PKR (Fengnase. This is particularly notable because the heme-
regulated kinase utilizes the same substrate (London et et al., 1992).
PKR has a well-recognized role in mediating the antivi-al., 1987) and its cDNA has 42% nucleotide identity with
human PKR (Chen et al., 1991). Thus the RI and hRI ral effects of interferon (Pestka et al., 1987; Hovanessian,
1989). In nonviral systems, its roles as a tumor suppres-peptide sequence appears to delineate a unique RNA
binding region within mouse and human PKR with regula- sor (Koromilas et al., 1992; Meurs et al., 1993), as a regu-
lator of cell growth and differentiation (Petryshyn et al.,tory properties.
Recently, a role for arginine residues and a-helix struc- 1988, 1984, 1996; Judware and Petryshyn, 1991; Ho-
vanessian, 1989; Bischoff and Samuel, 1989; Chong etture has been proposed for the recognition of RNA by
RNA binding proteins (Tan et al., 1993). Moreover, a sin- al., 1992; Belhumeur et al., 1993), and as a modifier of
signal transduction (Leonardo et al., 1989; Kumar et al.,gle arginine residue has been identified in the Tat protein
which accounts for the specific interaction with the bulge 1994; Maran et al., 1994) are now well established. Be-
cause of these properties it is clearly important to identifyregion of TAR RNA, while other arginines aid in promot-
ing specificity and stability (Puglisi et al., 1993). Several regions within PKR which regulate its biological activity.
Of equal significance is the possible translational roleRNA binding motifs have been predicted through com-
parative homology searches of the amino acid sequence which PKR plays in regulating the life cycle of HIV-1
(Edery et al., 1989). Several studies have indicated thatdata (Burd and Dreyfuss, 1994) including the two dsRNA
binding motifs present in the N-terminal portion of PKR the Tat protein binding region found in all HIV-1 mRNAs,
called TAR RNA, is capable of binding and activating(RI and hRI peptides). Peptides have been used success-
fully to test models for predicting secondary structure PKR (Edery et al., 1989; SenGupta and Silverman, 1989;
Judware et al., 1993; Maitra et al., 1994). This activation(Shoemaker et al., 1985). It is of interest that peptides as
short as 16 residues but enriched in alanines can form is inhibited by Tat protein (Judware et al., 1993; Maitra
et al., 1994), apparently depending on the availability ofstable a-helical structures in aqueous solution (Mar-
qusee et al., 1989). Apparently, alanine residues have a the Tat protein to compete with PKR for the TAR RNA.
Thus, identification and expression of peptide sequenceshigh potential to promote a-helical structure (Marqusee
et al., 1989). Taken together these findings suggest that which disrupt the TAR RNA–PKR–Tat axis could prove
to be a beneficial therapeutic approach against HIV-1RNA binding proteins require motifs which contain both
basic amino acids (e.g., arginine) to form hydrogen bonds infection.
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